SCHEMBL25002970

SCHEMBL25002970

COc1cc(/C=N/NC(=O)c2ccnc(-c3ccc(OC(F)(F)F)cc3)c2)cc(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 1/20 0.56
▸ GCGR P47871 3/20 0.56
▸ MAPT P10636 3/20 0.51
▸ POLB P06746 2/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ MGAM O43451 1/20 0.49
▸ ABL1 P00519 1/20 0.49
▸ KMT2A Q03164 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 4/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.45
▸ KDM1A O60341 2/20 0.45
▸ HDAC1 Q13547 2/20 0.45
▸ HDAC6 Q9UBN7 2/20 0.45
▸ KDM5A P29375 1/20 0.44
▸ KDM2B Q8NHM5 1/20 0.44
▸ KDM4C Q9H3R0 1/20 0.44
▸ KDM5B Q9UGL1 1/20 0.44
▸ TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27237421 1.00 SCN10A (0.56) SCN10AGCGRMAPTPOLBKDM4E
SCHEMBL27237474 0.91 MGAM (0.55) MAPTPOLBKDM4EMGAMKMT2A
SCHEMBL25003149 0.91 MGAM (0.55) MAPTPOLBKDM4EMGAMKMT2A
SCHEMBL27237375 0.86 POLB (0.53) MAPTPOLBKDM4EMGAMKMT2A
SCHEMBL25002971 0.86 POLB (0.53) MAPTPOLBKDM4EMGAMKMT2A
SCHEMBL25002969 0.86 MGAM (0.52) SCN10AMAPTPOLBKDM4EMGAM
SCHEMBL30950965 0.86 MGAM (0.52) SCN10AMAPTPOLBKDM4EMGAM
SCHEMBL27237429 0.86 MGAM (0.52) SCN10AMAPTPOLBKDM4EMGAM
SCHEMBL30862202 0.86 ALDH1A1 (0.52) SCN10AGCGRMAPTPOLBKDM4E
SCHEMBL27237438 0.86 ALDH1A1 (0.52) SCN10AGCGRMAPTPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335420-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2024-10-10 — — US claimed
EP-4382101-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2024-06-12 — — EP claimed
CN-118076347-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN claimed
US-20240335420-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2024-10-10 — — US disclosed
EP-4382101-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2024-06-12 — — EP disclosed
CN-118076347-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN disclosed
WO-2023010192-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335420-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS SCN1A, SCN1B, CACNA1B SCN10A 20/4885GCGR 2242/4885MAPT 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback